The PALOMA-3 trial assessed endocrine therapy resistance by tumor PIK3CA mutational status in circulating DNA at baseline, but neither the PIK3CA status nor the hormone receptor expression level significantly affected the treatment response [5]. This evidence concerns the gene NR4A1 and neoplasm.